NCT04606901View on ClinicalTrials.gov

Comparison of Time to Extubation Using Sugammadex or Neostigmine

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2023

Conditions
Neuromuscular BlockadeChronic Obstructive Pulmonary Disease
Interventions
DRUG

neostigmine/glycopyrrolate

neuromuscular blockade reversal agents

DRUG

sugammadex

neuromuscular blockade reversal agent

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Temple University

OTHER